Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 120


Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases.

Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, Dumontet C, Michallet M, Thomas X.

Leuk Res. 2011 Aug;35(8):1027-31. doi: 10.1016/j.leukres.2011.02.015. Epub 2011 Mar 12.


Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: a retrospective study of 54 cases.

Colita A, Belhabri A, Chelghoum Y, Charrin C, Fiere D, Thomas X.

Ann Oncol. 2001 Apr;12(4):451-5.


[Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].

Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX.

Zhonghua Xue Ye Xue Za Zhi. 2005 Dec;26(12):705-9. Chinese.


Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.


Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.

Hu XM, Liu F, Zheng CM, Li L, Liu C, Zhang SS, Xiao HY, Yang XH, Wang HZ, Xu YG, Hu NP, Ma R.

Chin J Integr Med. 2009 Jun;15(3):193-7. doi: 10.1007/s11655-009-0193-x. Epub 2009 Jul 2.


Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Tavernier E, Le QH, Elhamri M, Thomas X.

Leuk Res. 2003 Mar;27(3):205-14.


Long-term outcomes of de novo acute myeloid leukemia in Thai patients.

Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.

J Med Assoc Thai. 2009 Sep;92(9):1143-9.


Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland.

Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F, Ghielmini M.

Tumori. 2009 May-Jun;95(3):303-10.


Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I, Hunault-Berger M, Recher C, Lioure B, Himberlin C, Escoffre-Barbe M, Berthou C, Lissandre S, Fegueux N, Cahn JY, Jourdan E, Dreyfus F, Reiffers J, Milpied N, Ifrah N.

J Clin Oncol. 2010 Jun 20;28(18):3028-34. doi: 10.1200/JCO.2009.26.4648. Epub 2010 May 17.


A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study.

Cancer. 2005 Dec 15;104(12):2726-34.


Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0).

Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G.

Blood. 1994 Mar 15;83(6):1619-25.


Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.

Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD.

Leuk Res. 2004 Jan;28(1):43-8.


Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.


Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

Mi Y, Xue Y, Yu W, Liu S, Zhao Y, Meng Q, Bian S, Wang J.

Leuk Lymphoma. 2008 Mar;49(3):524-30. doi: 10.1080/10428190701836852.


[HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].

Liu H, Qian WB, Mai WY, Meng HT, Tong HY, Tong Y, Mao LP, Huang J, Wang L, Jiang DZ, Jin J.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jan;29(1):9-12. Chinese.


Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.

Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, Medeiros BC.

Am J Hematol. 2010 Nov;85(11):877-81. doi: 10.1002/ajh.21857.


Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL.

J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14.


[Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].

Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX.

Ai Zheng. 2006 Aug;25(8):1007-12. Chinese.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk